Mason Street Advisors LLC acquired a new stake in Eli Lilly and Co. (NYSE:LLY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 130,839 shares of the company’s stock, valued at approximately $10,304,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cullinan Associates Inc. raised its position in Eli Lilly and by 0.9% in the first quarter. Cullinan Associates Inc. now owns 32,367 shares of the company’s stock valued at $2,331,000 after buying an additional 300 shares during the last quarter. Lowe Brockenbrough & Co. Inc. raised its position in Eli Lilly and by 0.6% in the first quarter. Lowe Brockenbrough & Co. Inc. now owns 11,290 shares of the company’s stock valued at $813,000 after buying an additional 65 shares during the last quarter. Logan Capital Management Inc. raised its position in Eli Lilly and by 1.0% in the first quarter. Logan Capital Management Inc. now owns 32,835 shares of the company’s stock valued at $2,364,000 after buying an additional 335 shares during the last quarter. Iguana Healthcare Management LLC purchased a new position in Eli Lilly and during the first quarter valued at approximately $5,231,000. Finally, Squarepoint Ops LLC purchased a new position in Eli Lilly and during the first quarter valued at approximately $7,579,000. 74.98% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and Co. (NYSE:LLY) opened at 77.67 on Monday. Eli Lilly and Co. has a 1-year low of $67.88 and a 1-year high of $88.16. The stock has a market cap of $82.15 billion, a price-to-earnings ratio of 33.78 and a beta of 0.28. The firm has a 50-day moving average price of $78.23 and a 200 day moving average price of $77.96.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The company earned $5.19 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.89 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Co. will post $3.55 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s dividend payout ratio is presently 88.70%.

Several research firms have commented on LLY. Citigroup Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, August 3rd. Argus lifted their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a research note on Friday, July 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 27th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research note on Sunday, October 9th. Two analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $96.74.

In other news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.